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ANTIVIRAL THERAPY
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SUMMARY
The complex interaction between hepatitis C virus infection, iron homeostasis and the response to antiviral treatment remains 
controversial. The aim of this study was to evaluate the influence of hepatic iron concentration (HIC) on the sustained virological 
response (SVR) to antiviral therapy in patients with chronic hepatitis C. A total of 50 patients who underwent pretreatment liver biopsy 
with assessment of HIC by graphite furnace atomic absorption spectroscopy and were subsequently submitted to antiviral treatment 
with interferon/peginterferon and ribavirin were included in the study. Patients with alcoholism, history of multiple blood transfusion, 
chronic kidney disease, hemolytic anemia and parenteral iron therapy were excluded. The iron related markers and HIC were compared 
between those who achieved an SVR and non-responders (NR) patients. The mean age was 45.7 years and the proportion of patients’ 
gender was not different between SVR and NR patients. The median serum iron was 138 and 134 µg/dL (p = 0.9), the median serum 
ferritin was 152.5 and 179.5 ng/mL (p = 0.87) and the median HIC was 9.9 and 8.2 µmol/g dry tissue (p = 0.51), for SVR and NR 
patients, respectively. Thus, hepatic iron concentration, determined by a reliable quantitative method, was not a negative predictive 
factor of SVR in patients with chronic hepatitis C presenting mild to moderate hepatic iron accumulation.
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INTRODUCTION
Iron is an essential element for all living organisms and the complex 
interaction between iron homeostasis and human viral infections remains 
a challenging issue13. 
The association between hepatitis C virus (HCV) infection and altered 
serum iron profile or hepatic iron deposits has been evaluated in several 
studies6,9,36, but the prevalence of hepatic iron overload, its relationship 
with the severity of disease and its influence on the response to antiviral 
treatment are still controversial14,15,27,34,35.
Despite marked advances in the treatment of HCV infection, 
sustained elimination of the virus is not achieved in almost half the 
patients even with the current combined treatment of peginterferon 
and ribavirin18. Several viral and host factors such as HCV genotype, 
age, gender and degree of fibrosis are associated with the response to 
treatment, but the impact of hepatic iron deposits remains uncertain. 
Some studies have indicated that increased hepatic iron is one of the 
negative predictive factors of response to treatment2,7,24,29,33,40, but this 
fact has not been confirmed in other investigations1,12,20,22,31. However, it 
must be pointed out that most of these studies had not applied adequate 
methods of quantifying hepatic iron. 
The objective of the present study was to evaluate the influence of 
hepatic iron concentration (HIC) on the response to combined treatment 
with interferon/peginterferon and ribavirin in patients with chronic 
hepatitis C using a very accurate method of assessing hepatic iron content.
PATIENTS AND METHODS
This retrospective study identified patients with chronic hepatitis 
C (anti-HCV and HCV RNA positive) seen at the Hepatitis Outpatient 
Clinic of the Federal University of Sao Paulo, who were consecutively 
submitted to a pretreatment liver biopsy between May 2000 and August 
2001 and evaluated regarding HIC38. Among these patients, those who 
received antiviral treatment with interferon/peginterferon and ribavirin 
were included in the present study after giving their written informed 
consent. The protocol conformed to the ethical guidelines of the 1975 
Helsinki Declaration and was approved by the local Ethical Committee.
Exclusion criteria were alcohol consumption > 20 g/day, co-infection 
with HIV or HBV, immunosuppression, previous antiviral therapy, a 
history of multiple blood transfusions (> 6 units), chronic kidney disease, 
hemolytic anemia and parenteral iron therapy.
Assessment of biochemical and virological data and iron status 
by serum tests: Laboratory tests were carried out up to one month 
before or after the liver biopsy. Aspartate aminotransferase (AST, 
U/L) and alanine aminotransferase (ALT, U/L) were determined by 
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an automatized kinetic method and were reported as the number of 
times the upper limit of normal (ULN). Serum iron (normal value: 
37-145 µg/dL for women and 59-158 µg/dL for men) was measured 
by a colorimetric method (Olympus AU 640 Analyser, Tokyo, Japan) 
and serum ferritin (normal value: 5-200 ng/mL for women and 22-415 
ng/mL for men) was assayed by a chemiluminescence immunoassay 
(Access 2 Immunoassay System, Beckman Coulter Inc., Fullerton, 
CA, USA). Serum transferrin (normal value: 200-400 mg/dL) was 
determined by immunoturbidimetry (Olympus AU 640 Analyser, Tokyo, 
Japan) and its saturation was calculated using the following formula39: 
iron/transferrin x 71.2.
HCV RNA was detected by qualitative PCR using Amplicor kits 
(Cobas Amplicor HCV Test, Roche Diagnostic System, USA; detection 
limit: 50 IU/mL) and HCV genotyping was performed by sequencing 
the NS5B region of HCV30.
Evaluation of hepatic iron concentration in liver tissue: The 
quantification of iron in liver tissue was performed according to the 
modified method described by OLYNYK et al.28. To measure HIC, fresh 
liver specimens placed in a clean tube were dried to constant weight in a 
vacuum oven at 52 ºC. The dried samples were then weighed and placed in 
a tube containing 1 mL concentrated nitric acid and 1 mL ion-free water. 
Next the samples were digested in a microwave digestion system (MDS 
2000, USA). A blank and samples of bovine liver used as a reference 
material (1577b) were treated similarly. The resulting solutions were 
transferred to volumetric flasks and made up with ion-free water. All 
digested samples were diluted 1:8 in 0.2% nitric acid and a 10-µL volume 
was injected into the furnace for measurement. Iron concentration was 
determined by graphite furnace atomic absorption spectroscopy using 
a Varian Perkin-Elmer SIMAA-6000 spectrometer (USA). The results 
were expressed as µmol/g dry tissue weight. The hepatic iron index (HII), 
defined as the HIC to age ratio3, was also calculated.
Antiviral treatment of chronic hepatitis C: Treatment was 
indicated for patients with a degree of fibrosis ≥ 2 (Metavir classification4) 
in liver biopsies and consisted of combined administration of standard 
interferon (3MU three times weekly) or peginterferon (α2b 1.5 µg/kg 
or α2a 180 µg once-weekly) plus ribavirin (body weight < 75 kg: 1.0g/
day; ≥ 75 kg: 1.25g/day) for 24 to 48 weeks, according to the genotype.
Comparative analysis according to the response to treatment: 
The response to antiviral treatment was evaluated by the detection of 
HCV RNA in serum by qualitative PCR at the end of treatment and six 
months thereafter. Patients who tested HCV RNA negative in the sixth 
month post-treatment were classified as responders (sustained virological 
response, SVR). All other patients, including those who relapsed, were 
classified as non-responders (NR). The patients were compared regarding 
hepatic iron concentration (HIC) and serum iron profile according to the 
response to treatment (SVR or NR).
Statistical analysis: The results were first reported descriptively 
and then the association between variables of interest was investigated. 
Continuous variables were compared by the Student t-test or Mann-
Whitney test when appropriate. Categorical variables were compared 
using the chi-square test. A p value of less than 0.05 was considered 
statistically significant. Statistical analysis was performed by PASW 
Statistics 17.0 (SPSS Inc., Chicago, IL).
RESULTS
Among the 96 patients evaluated regarding HIC (previously reported 
results38), 50 underwent antiviral treatment for chronic hepatitis C (39 
with interferon + ribavirin and 11 with peginterferon + ribavirin) and were 
included in the present study. The mean age was 45.7 years (28-70), the 
mean duration of HCV infection was 20 years and there was predominance 
of male gender (60%). Hepatitis C virus genotyping was performed for 
35 patients and resulted in type 1 in 27 (77%) and type 3 in eight (23%). 
Sustained virological response was achieved in 18 patients (36%). Among 
patients infected with HCV genotype 1 and 3, the rates of sustained 
virological response were 26% and 25%, respectively (p > 0.05). Proportion 
of patients’ gender was not significantly different between SVR and NR 
patients (female/male: 7/11 vs 13/19, respectively, p = 0.90).
The demographic and clinical characteristics of the patients are 
shown in Table 1.
Table 1
Demographic and clinical characteristics of the sample studied
Characteristics n = 50
Sex
     Male/female 30/20
Age (years) 45.7 ± 10.2
Duration of HCV infection (years) 20.4 ± 8.8
HCV genotype (%)
     Type 1 77
     Type 3 23
Histology
     Fibrosis stage 3/4 Metavir (%) 20
Hemoglobin (g/dL) 14.8 ± 1.1
Hematocrit (%) 45.0 ± 3.2
Platelet count (x104/mm3) 18.5 ± 6.0
ALT (xULN) 2.4 (1.6-3.4)
AST (xULN) 1.8 (1.5-2.8)
Serum iron (µg/dL) 136.5 (104.0-162.2)
Serum ferritin (ng/mL) 164.0 (86.9-352.0)
Serum transferrin (mg/dL) 310.6 ± 50.1
Transferrin saturation (%) 33.5 ± 13.2
HIC (µmol/g dry tissue) 8.4 (4.8-13.3)
Hepatic iron index 0.18 (0.09-0.36)
Quantitative variables are expressed as mean ± SD or median (interquartile 
range). HCV, hepatitis C virus; ALT, alanine aminotransferase; ULN, upper limit 
of normal; AST, aspartate aminotransferase; HIC, hepatic iron concentration.
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No difference was observed in serum iron, serum ferritin and 
transferrin saturation between responders and non-responders. HIC did 
not influence the SVR rate (Fig. 1). Table 2 shows the serum and hepatic 
iron profile of responders and non-responders patients.
DISCUSSION
Chronic hepatitis C has been associated with the accumulation of 
iron in the liver, which could interfere with the response to antiviral 
treatment. However, studies evaluating the effect of iron on treatment 
in this population are extremely conflicting in terms of the method used 
for the determination of hepatic iron content, the adopted therapeutic 
regimen and the evaluation of response to treatment.
In the present investigation, the gold standard for the evaluation of 
HIC was adopted, i.e., quantification of iron in liver tissue specimens 
and the adopted antiviral therapy included either standard interferon 
or peginterferon, both with ribavirin. The results demonstrated that 
severe iron overload was a rare event among HCV-infected patients 
and HIC was not associated with the SVR to treatment with interferon/
peginterferon plus ribavirin. In fact, hepatic iron content has been shown 
to be low in most patients infected with HCV8,17,25. In the present study, 
patients with possible other causative factors of iron deposition, such 
as multiple blood transfusion and hemolytic anemia were excluded. 
Thus, our results reflect the HIC in patients infected with HCV 
without confounding factors of secondary iron overload. Moreover, 
the proportion of patients’ gender was similar between responders 
and non-responders and thus it is unlikely that the distinct serum and 
hepatic iron profiles between men and women have influenced the 
present analysis. The lack of association between HCV genotypes and 
the rate of SVR observed in our study is likely due to the low number 
of patients with this analysis available.
Early studies regarding HIC and monotherapy with standard 
interferon have only evaluated the impact on the biochemical response. 
VAN THIEL et al.40 studied 79 patients treated with interferon for six 
months and showed that the biochemical response (defined as complete 
normalization of ALT) or partial response (defined as a > 50% reduction 
in ALT levels six months after the end of treatment) was worse in patients 
with a higher HIC. Soon thereafter, in 1995, BARTON et al.2 found that 
the pattern of iron distribution in the liver was significantly different 
between patients with and without a complete biochemical response, also 
defined as normalization of ALT. OLYNYK et al.29 reported higher HIC 
in biochemical non-responders to interferon therapy for six months than 
in those with good response. Similar findings were reported by PIPERNO 
et al.33, who observed an association between higher hepatic iron content 
and a poor biochemical response in patients with chronic hepatitis C 
treated with standard interferon for 12 months. It should be emphasized 
that 80% of the patients with elevated HIC presented genotype 1b. Also 
in that study, iron depletion by phlebotomy performed on 16 patients 
subsequently treated with interferon did not improve the response to 
treatment despite improvement of ALT levels. 
On the other hand, studies evaluating virological response and 
hepatic iron determined by histological semiquantification have reported 
conflicting data. The results obtained in a group of patients with low 
levels (< 1mEq/mL) of HCV RNA1 treated with interferon for 24 weeks, 
showed higher iron-staining score in virological responders than in non-
responders and the investigators hypothesized that an optimal range of 
iron concentration may be beneficial for immune response. In contrast, 
Table 2
 Serum and hepatic iron profiles in patients presenting a sustained virological response (SVR) and in non-responders (NR)
SVR NR p
Serum iron (µg/dL) 138 (120.5 - 151.7) 134 (100.2 - 162.7) 0.90
Ferritin (ng/mL) 152.5 (93.6 - 326.5) 179.5 (81.6 - 352.0) 0.87
Transferrin (mg/dL) 315.2 ± 43.0 308.1 ± 54.3 0.46
Transferrin saturation (%) 32.5 ± 12.7 34.0 ± 13.6 0.69
HIC (µmol/g dry tissue) 9.9 (4.2 - 18.7) 8.2 (4.9 - 11.3) 0.51
Quantitative variables are expressed as mean ± SD or median (interquartile range). HIC, hepatic iron concentration.
Fig. 1 - Comparison of hepatic iron concentration between patients presenting sustained 
virological response and non-responders.
HIC, hepatic iron concentration; SVR, sustained virological response; NR, non-responders;*A 
60-year-old woman with hepatic iron concentration of 113.7 µmol/g; A 33-year-old man 
with hepatic iron concentration of 28.8 µmol/g; A 33-year-old man with hepatic iron 
concentration of 26,7 µmol/g.
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FUJITA et al.16 observed a significantly higher histological total iron score 
in patients not responding to combined interferon and ribavirin and LIN 
et al.24 found that positive hepatic iron stain predicted non-response to 
peginterferon and ribavirin therapy.
However, when hepatic iron levels were actually measured, recent 
publications12,22,31 did not find any influence of HIC on the SVR in patients 
undergoing combined therapy with standard interferon and ribavirin. 
To the best of our knowledge, only one study20 has previously 
evaluated the role of hepatic iron concentration (measured by atomic 
absorption spectrophotometry) in relation to the efficacy of chronic 
hepatitis C therapy schedule including peginterferon. In agreement 
with our results, HOFER et al.20 observed no difference in tissue iron 
concentration between patients who achieved an SVR and non-responders 
both submitted to combined interferon/peginterferon and ribavirin 
treatment. 
Even in cases of iron overload, as in thalassemic patients, two 
studies11,37 found no impact of excessive iron deposition on the SVR 
rate. In addition, demonstrating the efficacy of combined treatment with 
peginterferon and ribavirin in young thalassemic patients, one study21 
showed an SVR in 62.5% of cases, a rate similar to that observed in 
non-thalassemic patients.
The role of HFE genotype on hepatic iron in chronic hepatitis C is 
another interesting area of investigation. This issue has been addressed 
in several studies and controversial findings have been reported32. 
CORENGIA et al.8 studied 206 patients with chronic hepatitis C and 
found higher frequency of genotypes containing HFE mutations in 
the subgroup of patients with hepatic iron accumulation, whereas 
no significant difference was observed between the subgroup of 
patients without hepatic iron deposits and control subjects. They also 
demonstrated a significant association between HFE genotypes and 
iron deposition in hepatocellular compartment, but not in sinusoidal and 
portal areas, suggesting that the cause of hepatic iron accumulation in 
chronic hepatitis C could not be simply the release of iron from necrotic 
hepatocytes or the inflammatory-mediated perturbation of iron trafficking, 
when iron would accumulate preferentially in Kupffer cells.
But in another study, KAZEMI-SHIRAZI et al.23 assessed the HFE 
mutations in 184 patients with chronic hepatitis C and 487 controls and 
found no difference in hepatic iron content among patients with or without 
HFE mutations. In hepatitis C and control group, 32% and 29% of patients 
carried either mutations (C282Y and H63D), respectively. Histological 
iron grades 3 or 4 (Perls’ Prussian blue stain) were found in 23.4% and 
15.7% of chronic hepatitis C patients with and without mutation of the 
HFE gene, respectively, p = 0.36.
Interestingly, recent data5 from patients with advanced fibrosis (part 
of the HALT-C study) showed that the presence of mutations in the 
HFE gene (especially the most common H63D mutation) resulted in 
a higher chance of an SVR during retreatment with peginterferon and 
ribavirin, with the observation of a direct correlation with ferritin and 
semiquantified histological iron levels. Although we did not investigate 
mutations of hereditary hemochromatosis in this study, none of the 
patients presented an HII suggestive of this disease, i.e., higher than 1.93. 
In addition, there is evidence indicating that the prevalence of this disease 
among patients infected with HCV does not differ from that found in 
the general population23,26.
The lack of a correlation between HIC and response of patients with 
hepatitis C to antiviral treatment agrees with the majority of the results 
regarding phlebotomy as coadjuvant treatment7,10,19. DI BISCEGLIE et 
al.10 showed that in patients with hepatitis C not responding to interferon 
monotherapy iron depletion by phlebotomy did not result in a higher 
SVR rate during retreatment, despite an association with improved liver 
injury manifested by a decrease in transaminases and improved liver 
histopathology after phlebotomy. Similarly, in the study of HERRERA19 
iron depletion by phlebotomy did not improve SVR in the retreatment 
of patients who were previously non-responders. But on the contrary, in 
the study of CARLO et al.7 83 patients were randomly assigned to be 
submitted to iron depletion before interferon monotherapy and a better 
complete response (biochemical and virological) was achieved in the 
phlebotomy group.
In conclusion, hepatic iron concentration determined by a reliable 
quantitative method, was not a negative predictive factor of SVR 
to antiviral treatment with interferon/peginterferon and ribavirin in 
patients with chronic hepatitis C presenting mild to moderate hepatic 
iron accumulation.
RESUMO
Hepatite C crônica: concentração hepática de ferro não é 
correlacionada com a resposta ao tratamento antiviral
A complexa interação entre infecção pelo vírus da hepatite C, 
homeostase do ferro e resposta ao tratamento antiviral permanece 
controversa. O objetivo deste estudo foi avaliar a influência da 
concentração hepática de ferro (CHF) na resposta virológica sustentada 
(RVS) à terapia antiviral na hepatite C crônica. Foram incluídos 50 
pacientes que foram submetidos à biopsia hepática pré-tratamento com 
determinação da CHF por espectrofotometria de absorção atômica com 
forno de grafite e tratados posteriormente com interferon/peginterferon 
e ribavirina. Pacientes com alcoolismo, história de múltiplas transfusões 
sanguíneas, doença renal crônica, anemia hemolítica e terapia com 
ferro parenteral foram excluídos. O perfil de ferro sérico e a CHF foram 
comparados entre aqueles que atingiram RVS e os não-respondedores 
(NR). A média de idade dos pacientes foi 45,7 anos e não houve 
diferença na proporção de homens e mulheres entre os grupos RVS 
e NR. A mediana do ferro sérico foi 138 and 134 µg/dL (p = 0.9), a 
mediana da ferritina sérica foi 152,5 e 179,5 ng/mL (p = 0,87) e a CHF 
mediana foi 9,9 e 8,2 µmol/g de tecido seco (p = 0,51), para pacientes 
com RVS e NR, respectivamente. Concluindo, a concentração hepática 
de ferro, determinada por um método quantitativo confiável, não foi um 
fator preditivo negativo de RVS em pacientes com hepatite C crônica e 
acúmulo de ferro hepático leve a moderado.
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